Abstract
Mendelian randomization and colocalization are two statistical approaches that can be applied to summarized data from genome-wide association studies (GWASs) to understand relationships between traits and diseases. However, despite similarities in scope, they are different in their objectives, implementation, and interpretation, in part because they were developed to serve different scientific communities. Mendelian randomization assesses whether genetic predictors of an exposure are associated with the outcome and interprets an association as evidence that the exposure has a causal effect on the outcome, whereas colocalization assesses whether two traits are affected by the same or distinct causal variants. When considering genetic variants in a single genetic region, both approaches can be performed. While a positive colocalization finding typically implies a non-zero Mendelian randomization estimate, the reverse is not generally true: there are several scenarios which would lead to a non-zero Mendelian randomization estimate but lack evidence for colocalization. These include the existence of distinct but correlated causal variants for the exposure and outcome, which would violate the Mendelian randomization assumptions, and a lack of strong associations with the outcome. As colocalization was developed in the GWAS tradition, typically evidence for colocalization is concluded only when there is strong evidence for associations with both traits. In contrast, a non-zero estimate from Mendelian randomization can be obtained despite only nominally significant genetic associations with the outcome at the locus. In this review, we discuss how the two approaches can provide complementary information on potential therapeutic targets.
Original language | English |
---|---|
Pages (from-to) | 767-782 |
Number of pages | 16 |
Journal | American Journal of Human Genetics |
Volume | 109 |
Issue number | 5 |
DOIs | |
Publication status | Published - 5 May 2022 |
Bibliographical note
Funding Information:S.B. is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society ( 204623/Z/16/Z ). C.W. is funded by the Wellcome Trust ( WT220788 ). This research was funded by United Kingdom Research and Innovation Medical Research Council ( MC_UU_00002/4 and MC_UU_00002/7 ), GSK , and MSD , and was supported by the National Institute for Health Research Cambridge Biomedical Research Centre ( BRC-1215-20014 ). The views expressed are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health and Social Care. This research has been conducted using the UK Biobank Resource under Application Number 7439.
Funding Information:
S.B. is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (204623/Z/16/Z). C.W. is funded by the Wellcome Trust (WT220788). This research was funded by United Kingdom Research and Innovation Medical Research Council (MC_UU_00002/4 and MC_UU_00002/7), GSK, and MSD, and was supported by the National Institute for Health Research Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health and Social Care. This research has been conducted using the UK Biobank Resource under Application Number 7439. D.G. is a part-time employee of Novo Nordisk. I.M. and C.W. are wholly or partially funded by a grant from GSK and MSD. The other authors have no relevant conflict of interest to declare.
Funding Information:
D.G. is a part-time employee of Novo Nordisk. I.M. and C.W. are wholly or partially funded by a grant from GSK and MSD. The other authors have no relevant conflict of interest to declare.
Publisher Copyright:
© 2022 American Society of Human Genetics